Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Journal of Hepatology - Tập 76 Số 4 - Trang 862-873 - 2022
Ann‐Lii Cheng1, Shukui Qin2, Masafumi Ikeda3, Peter R. Galle4, Michel Ducreux5, Tae‐You Kim6, Ho Yeong Lim7, Masatoshi Kudo8, В. В. Бредер9, Philippe Merle10, Ahmed O. Kaseb11, Daneng Li12, Wendy Verret13, Ning Ma14, Alan Nicholas15, Yifan Wang16, Lindong Li17, Andrew X. Zhu18,19, Richard S. Finn20
1Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan
2Department of Medical Oncology, People’s Liberation Army Cancer Center, Nanjing, People’s Republic of China
3Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
4Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
5Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France
6Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
7Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
8Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan
9Department of Chemotherapy, N.N.Blokhin Russian Cancer Research Center, Moscow, Russia
10Department of Gastroenterology and Hepatology, University Hospital La Croix-Rousse, Lyon, France
11Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
12Department of Medical Oncology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
13Product Development Oncology, Genentech Inc., South San Francisco, CA, USA
14Product Development Safety, Genentech, Inc., South San Francisco, CA, USA
15Product Development Biostatistics, Genentech, Inc., South San Francisco, CA, USA
16Product Development Biostatistics, Roche Product Development, Shanghai, People’s Republic of China
17Product Development Medical Affairs, Roche Product Development, Shanghai, People’s Republic of China
18Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA
19Jiahui International Cancer Center, Jiahui Health, Shanghai, People’s Republic of China
20Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492

Giannini, 2015, Prognosis of untreated hepatocellular carcinoma, Hepatology, 61, 184, 10.1002/hep.27443

Johnson, 2013, Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 31, 3517, 10.1200/JCO.2012.48.4410

Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1

Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857

Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745

2019

2020

Hegde, 2018, Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics, Semin Cancer Biol, 52, 117, 10.1016/j.semcancer.2017.12.002

Wallin, 2016, Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma, Nat Commun, 7, 12624, 10.1038/ncomms12624

Siegel, 2008, Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma, J Clin Oncol, 26, 2992, 10.1200/JCO.2007.15.9947

Lee, 2020, Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study, Lancet Oncol, 21, 808, 10.1016/S1470-2045(20)30156-X

Zhu, 2020, Abstract CT044: genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC), Cancer Res, 80, CT044, 10.1158/1538-7445.AM2020-CT044

Cheng, 2013, Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 31, 4067, 10.1200/JCO.2012.45.8372

Cainap, 2015, Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, J Clin Oncol, 33, 172, 10.1200/JCO.2013.54.3298

Zhu, 2015, SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 33, 559, 10.1200/JCO.2013.53.7746

Ren, 2020, Abstract LBA2: sintilimab plus bevacizumab biosimilar vs. sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2, Ann Oncol, 31, S1287, 10.1016/j.annonc.2020.10.134

Ducreux, 2021, J Clin Oncol, 39, 10.1200/JCO.2021.39.15_suppl.4071

Sangro, 2020, Abstract LBA-3: CheckMate 459: long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma, Ann Oncol, 31, S241, 10.1016/j.annonc.2020.04.078

Gandara, 2018, Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study, J Thorac Oncol, 13, 1906, 10.1016/j.jtho.2018.08.2027

Thông tin
Thông tin xuất bản

Journal of Hepatology

Tập 76 Số 4

862-873

Thông tin tác giả